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REVIEW CURRENTOPINION Genetic contribution to osteoarthritis development:
current state of evidence Copyright 
www.co-rheumatology.comJohn LoughlinPurpose of review
Powerful association studies have identified a number of genetic signals that can be confidently judged as
associated with osteoarthritis. Efforts have continued to discover new loci, whilst functional studies are being
applied to assess which genes are the likely targets of the risk-conferring alleles. The study of epigenetics has
highlighted an interaction between osteoarthritis genetics and DNA methylation. This review will summarize
some of the recent key studies in osteoarthritis genetics, including functional and epigenetic analyses.
Recent findings
Several novel osteoarthritis susceptibility loci have been reported recently, including the regulatory genes
NCOA3 and ALDH1A2. Functional analyses of these genes and of others reported previously support
earlier suggestions that osteoarthritis susceptibility is principally mediated by modulations to gene
expression. DNA methylation analyses provide additional insights into the osteoarthritis disease process, at
both a genome-wide level and when investigating direct interactions with risk-conferring alleles.
Summary
Osteoarthritis genetic risk predominantly acts by modulating gene expression, an effect typically mediated
via transcriptional regulation. Effects on various pathways have been detected, including cell differentiation
and cartilage homeostasis. The continued identification of risk loci, their functional study, and the
unification of genetic and epigenetic analyses will be key themes in the future.
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Epidemiological investigations of the past, includ-
ing twin-pair analyses and family-based segregation
studies, provided clear evidence of a heritable com-
ponent to osteoarthritis susceptibility. These studies
stimulated the initial search for osteoarthritis risk
alleles. Osteoarthritis susceptibility is coded for by
DNA polymorphism [principally single-nucleotide
polymorphisms (SNPs)] and as such these studies
involved a comparison of the frequency of poly-
morphisms in individuals with the disease (cases)
versus those without (disease-free controls), or those
in whom osteoarthritis status had not been deter-
mined (population controls). Such case-control
studies have tremendous power, so long as certain
criteria are met. These include: an analysis of an
adequate number of cases and controls, to account
for the relatively modest effect individual risk alleles
have on disease cause; the analysis of an appropriate
number of polymorphisms, to account for the
extensive genetic variation within the genome;
the use of cases and controls drawn from the same© 2015 Wolters Kluwer ethnic group, to avoid stratification (and false-posi-
tives) resulting from the natural variation in gene
frequencies between different population groups;
and the use of an unambiguous disease phenotype.
This latter requirement is one that particularly taxes
osteoarthritis researchers, with numerous choices
available, ranging from symptom-free radiographic
disease through to severe, painful end-stage
osteoarthritis necessitating joint replacement. TheHealth, Inc. All rights reserved.
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KEY POINTS
 Osteoarthritis genetic risk loci have small individual
effects, but they can be identified so long as cohort
sample size is adequate and the phenotype is robust.
 Effects on gene expression appear to be the common
mechanism by which osteoarthritis risk-conferring alleles
mediate their effect.
 A range of informative functional tools are now
available to osteoarthritis geneticists, including access
to relevant cells and tissues, removing any excuses for
not following up interesting genetic hits.
 Epigenetic analyses, in particular DNA methylation
studies, are clarifying how genetic effects interact with,
and are modulated by, the genome and the
environment. This may be the most exciting discovery to
have emerged in the past year or two.
Genetic contribution to osteoarthritis development Loughlinskeletal site to be studied is also a source of debate;
disease of the knee or hip has dominated in the past
decade, but the hand is now making a comeback,
whilst other skeletal sites remain under-investi-
gated. The past decade has seen a number of reason-
ably powered osteoarthritis case-control studies, in
the form of candidate gene-based analyses or
genome-wide association studies (GWAS). In the
past few years, the focus has started to shift to
functional analyses of genes implicated from these
genetic studies, and to an analysis of the role of
epigenetics in osteoarthritis and its interaction with
risk-conferring alleles. This review will touch on
these areas, with a particular focus on novel and
insightful discoveries from the past 18 months.OSTEOARTHRITIS GENETIC ASSOCIATION
STUDIES
The most powerful osteoarthritis GWAS performed
to date was published in 2012 and entailed an
analysis of over 7400 osteoarthritis cases [1]. This
study, termed arcOGEN, was the first GWAS to
report multiple, independent association signals
that replicated at a level considered significant after
accounting for the multiple tests that are performed
in a GWAS (P value<5108). arcOGEN investi-
gated patients with hip or knee osteoarthritis and
clearly demonstrated that, at the molecular genetic
level, osteoarthritis risk is not uniform between
these two skeletal sites: a polymorphism can be
associated with disease at the hip without showing
any evidence of association at the knee. Epidemio-
logical studies are also revealing that osteoarthritis
pathophysiology is not uniform across the skeleton
[2]. As such, genetic studies are substantiating these Copyright © 2015 Wolters Kluwe
1040-8711 Copyright  2015 Wolters Kluwer Health, Inc. All rights resefinds. A bioinformatics analysis of the association
signals that emerged from arcOGEN, and from less
powerful GWAS and candidate gene-based studies,
highlighted a number of biological pathways
through which osteoarthritis genetic susceptibility
is operating [3]. These include skeletogenesis,
encompassing development and differentiation of
osteoblasts and chondrocytes, with transcriptional
regulation and cell signaling key. Since the arc-
OGEN publication, there have been four additional
osteoarthritis genetic association papers published
in which the investigators have utilized large
cohorts andwhich have added to our understanding
of the molecular basis of this disease.FOUR RECENT EXAMPLES
A meta-analysis of over 78000 Europeans has ident-
ified a genome-wide significant signal associated
with hip osteoarthritis [4
&&
]. The signal, at chromo-
some 20q13, is marked by SNP rs6094710, with a
genome-wide significant P value of 7.9109 and
an odds ratio (OR) of 1.28. This SNP is located
upstream of two very plausible candidate genes
for osteoarthritis: NCOA3, which codes for nuclear
receptor coactivator 3, and SULF2, which codes for
an extracellular heparan sulfate 6-O endosulfatase 2.
Both genes are expressed in cartilage, with expres-
sion of NCOA3 reduced in osteoarthritis-affected
cartilage compared with preserved cartilage from
the same joint [4
&&
], and with SULF2 expression
increased in osteoarthritis cartilage as compared
with normal cartilage [5]. rs6094710 is in perfect
linkage disequilibrium (r2¼1, D0 ¼1) with several
other SNPs within the 20q13 region; these SNPs
co-segregate without recombination and as such it
is not possible, genetically, to determine which SNP
is responsible for the association signal. Instead,
direct functional investigations of the SNPs will be
required. One of the SNPs, rs6094752, codes for an
amino acid change within the NCOA3 protein.
However, this change is benign when examined
using protein prediction tools. No other SNPs alter
amino acid sequence of the NCOA3 or SULF2
proteins, and as such it appears likely that the
association signal acts bymodulating the expression
of NCOA3 or SULF2, or possibly both genes.
The first powerful GWAS of hand osteoarthritis
has identified a signal at chromosome 15q22,
marked by SNP rs3204689, with a genome-wide
significant P value of 1.11011 and an OR of
1.46 [6
&&
]. This SNP is located in the 3’ untranslated
region (3’UTR) of the gene ALDH1A2, which codes
for an enzyme involved in retinoic acid synthesis. As
the authors note in their report, retinoic acid is
a signaling molecule involved in a variety ofr Health, Inc. All rights reserved.
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Intriguingly, rs3204689 was not associated with
osteoarthritis at other skeletal sites despite an
expression analysis of ALDH1A2, revealing that
the hand osteoarthritis risk-conferring C-allele of
the SNP correlates with reduced expression of the
gene in knee and hip cartilage from osteoarthritis
patients. Assuming that this functional effect is not
coincidental, it would therefore represent an
example of a functional effect (altered expression
of ALDH1A2 in knee and hip cartilage) not trans-
lating into a genetic risk, once again highlight-
ing the differing osteoarthritis pathophysiology
between different skeletal sites. To be confident that
reduced expression of ALDH1A2 is in fact causal for
hand osteoarthritis, an expression analysis of the
gene in relevant tissues from the finger joints of
osteoarthritis patients will be required.
A second recent hip osteoarthritis GWAS
reported a signal at chromosome 7p12.3, marked
by SNP rs788748, with a genome-wide significant
P value of 2.0108 and an OR of 0.71 [7]. Unlike
the above two reports, replication analysis per-
formed by the investigators led to the signal becom-
ing weaker rather than stronger, with a meta-
analysis P value of 1.0106. A less significant
P value following meta-analysis is very often the
sign of a false-positive. If that is the case, it may
have derived from the small sample size used in the
GWAS (only 654 cases), which will have limited its
power to detect a genuine signal. The investigators
nevertheless performed a number of functional
analyses on the gene located closest to rs788748,
IGFBP3, which codes for insulin-like growth factor-
binding protein 3. They discovered that knockdown
and overexpression of IGFBP3 protein had measur-
able effects compared to control treatments in sev-
eral chondrogenesis models, and reported that
genotype at rs788748 correlated with levels of
IGFBP3 in the blood. The question, however, is
whether these functional effects are enough to
assuage concerns about the reduced significance
of the association signal after replication. IGFBP3
clearly has a functional role, but that does not
automatically mean that its gene should be the
repository of osteoarthritis genetic risk. An assess-
ment of the association of rs788748 in additional
osteoarthritis cohorts, including the large arcOGEN
study, would therefore be wise.
The final example is ameta-analysis of European
osteoarthritis candidate gene studies [8
&
]. Before
GWAS became an affordable option, investigators
would choose their favorite gene and subject it to a
genetic association analysis. These studies would
often be performed on case-control cohorts of mod-
est size (typically only a few hundred individuals) Copyright © 2015 Wolters Kluwer 
286 www.co-rheumatology.comand with a small number of polymorphisms tested.
Osteoarthritis researchers succumbed to this
temptation as much as investigators in other disease
areas. Despite the fact that the majority of such
studies found no compelling evidence for an associ-
ation, there always seemed to be enough marginally
positive data to ensure some investigators kept the
faith. In fact, there has only been one osteoarthritis
candidate that has convincingly stood the test of
repeated analysis: GDF5, whose story has been told
before [9]. In the recent candidate analysis, the
investigates studied published reports from another
199 osteoarthritis candidates and confirmed that
none was overly compelling, with only the type
XI collagen gene COL11A1 and the vascular endo-
thelial growth factor gene VEGF demonstrating any
semblance of association. However, even their P val-
ueswerequitemodest comparedwith the signals that
have emerged from GWAS studies, with values
greater than 1106. This candidate studyhas there-
fore reinforced the need to maintain a hypothesis-
free approach when trying to identify osteoarthritis
risk loci. It also remindsus thatour comprehensionof
the disease is still somewhat nascent.
In summary, these four recent reports have
added to the genes that can be confidently con-
sidered as repositories of osteoarthritis genetic risk
(NCOA3/SULF2 and ALDH1A2); they have recon-
firmed the observation that osteoarthritis risk is
often acting by modulating gene regulation, that
functional analyses can be highly insightful, but
that vigilance and objectivity need to bemaintained
and applied when assessing the likelihood of an
association signal being genuine.EPIGENETIC EFFECTS
Epigenetics refers to heritable changes in gene
expression or phenotype that occur without
changes in the underlying DNA sequence. There
are three mechanisms of epigenetic gene regulation:
DNA methylation of CpG dinucleotides, post-trans-
lational modifications of histone proteins, and non-
coding RNAs such asmicroRNAs. They regulate gene
expression either by affecting gene transcription
(DNA methylation, histone modifications) or by
acting post-transcriptionally, leading to changes in
the levels of the encoded protein (e.g. microRNAs).
Epigenetic patterns are bothplastic, especially during
development and cell differentiation when they
undergo dynamic changes, and stable, allowing cel-
lular identify to be maintained during mitotic cell
divisions. A recent review provides an update on the
status of epigenetics in osteoarthritis [10].
The advent of high-throughput arrays for the
analysis of DNA methylation has significantlyHealth, Inc. All rights reserved.
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Genetic contribution to osteoarthritis development Loughlinboosted the amount of epigenetic data that has
emerged in the past few years. Osteoarthritis has
taken part in this enhanced activity and is in fact
quite well placed to do so, for two principal reasons:
the central tissue involved in the disease process,
cartilage, is readily accessible via joint replacement
surgery; and the cartilage contains only a single
cell type, the chondrocyte, thus limiting the
scope for confounding heterogeneity that can
be encountered when studying the epigenetics of
a multicellular tissue in which cell-specific effects
are likely.
Fivemethylation array analyses of cartilage DNA
have been published in the past 18 months, focused
on knee and/or hip osteoarthritis [11
&
,12–15]. A
number of interesting observations have emerged.
For example, knee and hip cartilages are strikingly
different, with DNA methylation differences at a
number of genes, including homeobox genes
[12,15], which are key regulators of skeletogenesis.
This is reminiscent of the joint-specific genetic
effects touched on earlier, and suggests that carti-
lages from different parts of the skeleton are not
only genetically but also epigenetically distinct. The
DNA methylation studies [11
&
,12–14] have also
revealed that genes that have previously been impli-
cated in osteoarthritis typically harbor CpG sites
that are differentially methylated between osteo-
arthritis and non-osteoarthritis cartilage. This
implies that the regulation of gene expression via
DNA methylation is a major driver of the osteo-
arthritis disease process.
An alternative avenue of investigation has been
to assess whether there is a direct, functional
relationship between epigenetics and genetics at
particular risk alleles. For example, could DNA
methylation changes impact the penetrance of a
nearby risk polymorphism? If the risk polymor-
phism modulates gene expression, then the methy-
lation status of the surrounding DNA could
attenuate or amplify the risk effect by regulating
expression of the gene. This is a particularly inter-
esting question in genetics, since epigenetic
changes can occur in response to environmental
factors, including diet, and during aging, leading
to the suggestion that a possible mechanism for
the late onset of common human diseases such as
osteoarthritis is the age-related loss of normal
epigenetic control. Two such studies directly inves-
tigating interactions between DNA methylation
and osteoarthritis risk-conferring alleles have been
reported, for the aforementioned GDF5 and for
DIO2.
The GDF5 functional SNP, rs143383, is a C/T
transition located in the 5’UTR of the gene. In its
C-allele form, it forms a CpG site. The SNP mediates Copyright © 2015 Wolters Kluwe
1040-8711 Copyright  2015 Wolters Kluwer Health, Inc. All rights resedifferential allelic expression (DAE)ofGDF5,with the
osteoarthritis risk-conferring T allele demonstrating
reduced expression due to the more avid binding of
repressor proteins, including DEAF1 [16]. rs143383 is
a particular risk factor for knee osteoarthritis [17].
Functional analyses using human transformed cell
lines, chondrocytes, and cartilages have highlighted
that differential DNA methylation of rs143383, and
ofCpG sites flanking the SNP,modulates the binding
of the repressor proteins and therefore alters the
expression differences between the C and T alleles
[18,19
&&
]. Furthermore, a CpG site located 4 base
pairs upstream of rs143383 shows highly significant
demethylation in osteoarthritis knee cartilage com-
pared with osteoarthritis hip cartilage, which corre-
lates with reduced expression of the gene [19
&&
]. This
may therefore account for why rs143383 is a parti-
cular risk factor for the knee: the combination of
an epigenetic effect leading to demethylation and
reduced expression of GDF5, combined with the
presence of the low-expressing T allele, may be
enough to make this a more penetrant osteoarthritis
allele in knee cases.
DIO2 codes for iodothyronine-deiodinase
enzyme type 2 (D2), a selenoprotein that converts
intracellular inactive thyroid hormone to its active
form. A common DIO2 haplotype composed of the
C-allele of SNP rs225014, and the C-allele of SNP
rs12885300 is associated with osteoarthritis [20]. An
analysis of DIO2 expression has revealed that, as for
GDF5, the gene is subject to DAE, with the C-allele of
rs225014 correlating with increased expression of
the gene in cartilage [21]. In a recent functional
analysis of DIO2, including DNA methylation
studies, it was reported that differential methylation
of CpGs located upstream of the gene correlated
withDIO2 expression changes, and that these effects
were particularly striking for individuals harboring
the risk-conferring allele of rs225014 [22
&
]. As for
GDF5, DIO2 is subject to epigenetic regulation
related to genotype.CONCLUSION
The genetic study of osteoarthritis susceptibility has
now evolved from the mapping of risk loci through
to their comprehensive functional analysis, com-
bined with detailed epigenetic investigations. We
have though only scratched the surface, with just a
handful of risk alleles so far identified. Osteoarthritis
is particularly polygenic [23] and as such large
cohorts are required to map osteoarthritis suscepti-
bility loci with confidence. The heterogeneity
between skeletal sites emphasizes that each needs
to be treated almost as a different genetic disease,
although, as with the emerging ALDH1A2 story, itr Health, Inc. All rights reserved.
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Osteoarthritismay be possible to do functional analyses on
cells or tissues from more accessible skeletal sites
that are not themselves impacted on by the risk-
conferring allele. More mapping, additional func-
tional studies, and further integration with other
genome-wide approaches will continue to be the
priorities for this common and particularly complex
human disease.
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